Instylla Logo
Instylla Verge Flow Tip
Clinical need

Embolization Treatment

Transcatheter embolization is a minimally invasive technique where catheter-directed embolic agents are delivered to stop blood vessels that are injured or bleeding or close off vessels supplying blood to a tumor.

While less invasive than open surgery, existing embolization treatments involve shortcomings requiring active management by interventional radiologists. These include:

  • Failure to deeply penetrate the tumor vascular bed allowing for continued tumor blood flow
  • Flow into healthy vessels leading to non-target embolization and healthy tissue injury
  • Dependence on blood coagulation to stop blood flow, potentially delaying occlusion in patients with compromised blood clotting
How it works

Water-based PEG Hydrogel Technology

Embrace™ Hydrogel Embolic System (HES) consists of two low viscosity liquid precursors that polymerize intravascularly when simultaneously injected into blood vessels forming a soft, water-based PEG hydrogel, during the embolization procedure.

Before use, the precursors are mixed with commercially available iodinated contrast media enabling radiopacity. The hydrogel contains no organic solvents in its formulation. Upon delivery, the hydrogel casts out the vasculature to create a rapid and durable occlusion. The hydrogel liquifies via hydrolysis over a period of approximately 6 months, and the hydrolysis products are absorbed and cleared via renal filtration.*

Solution

Hydrogel Embolic System

Embrace Hydrogel Embolic System (HES) is a minimally-invasive, vascular embolization treatment that interventional radiologists can potentially easily deliver with immediate, complete, and persistent embolization.**

Embrace Hydrogel Embolic System (HES)

Complete and Persistent Occlusion

Predictable and Effective Embolic

Easy and Accurate Delivery

Verge microcatheter for liquid embolic delivery
The Results

Effective at Embolizing Hypervascular Tumors

As demonstrated in the First-in-Human (FIH) study, Embrace HES was effective at embolizing malignant and benign hypervascular tumors by blocking tumor blood supply with technical success in all patients and persistent embolization as noted in imaging follow up at 30-days.*

Hepatocellular carcinoma (HCC) tumor. Images are courtesy Dr. Mark Goodwin.

Before and After Tumor Embolization - Patient #1

Hepatocellular carcinoma (HCC) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #2

Angiomyolipoma (AML) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #3

Angiomyolipoma (AML) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #4

Hepatocellular carcinoma (HCC) tumor. Images are courtesy Dr. Lu.

Before and After Tumor Embolization - Patient #5

Hepatocellular carcinoma (HCC) tumor. Images are courtesy Dr. Mark Goodwin.

Before and After Tumor Embolization - Patient #1

Hepatocellular carcinoma (HCC) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #2

Angiomyolipoma (AML) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #3

Angiomyolipoma (AML) tumor. Courtesy of Dr Andrew Holden, Auckland City Hospital, Auckland, New Zealand

Before and After Tumor Embolization - Patient #4

Hepatocellular carcinoma (HCC) tumor. Images are courtesy Dr. Lu.

Before and After Tumor Embolization - Patient #5

*Data on file at Instylla.

**Ganguli S, Lareau R, Jarrett T, Soulen MC, A Water-based Liquid Embolic: Evaluation of Safety and Efficacy in a Rabbit Kidney Model, Journal of Vascular and Interventional Radiology (2021), doi: https://doi.org/10.1016/j.jvir.2021.02.018